Azelnidipine
![]() | |
| Clinical data | |
|---|---|
| Trade names | CalBlock,AZUSA,Azovas |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.162.151 |
| Chemical and physical data | |
| Formula | C33H34N4O6 |
| Molar mass | 582.657 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| | |
Azelnidipine (INN; marketed under the brand name CalBlock — カルブロック) is a dihydropyridine calcium channel blocker. Azelnidipine is L and T calcium channel blocker. It is sold in Japan by Daiichi-Sankyo pharmaceuticals, Inc. Drug Controller General Of India (DCGI) has approved the use of azelnipine in India. It is launched under the brand name Azusa (ajanta pharma ltd.)[1] In 2020.
Unlike nicardipine, it has a gradual onset and has a long-lasting antihypertensive effect, with little increase in heart rate.
References
- ↑ Oizumi K, Nishino H, Koike H, Sada T, Miyamoto M, Kimura T (September 1989). "Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker". Jpn. J. Pharmacol. 51 (1): 57–64. doi:10.1254/jjp.51.57. PMID 2810942.Scholar search Archived 2021-09-30 at the Wayback Machine
